Browse studies

Find your next paid study

27,370 recruiting studies available now

A Multi-Site Clinical Evaluation of the LIAISON NES FLU A/B, RSV & COVID-19 Assay in Symptomatic Patients

The DiaSorin Molecular LIAISON® NES FLU A/B, RSV \& COVID-19 real-time polymerase chain reaction (RT-PCR) assay is intended for use on the DiaSorin LIAISON® NE…

Influenza aInfluenza BRSV+1 more

Estimated

~$10 – $1,050

Actual pay is set by the research site.

DiaSorin Molecular LLCNCT06672692

OneRF® Ablation System Post-Market Real-World Evidence Registry

This is a multi-site registry study that aims to collect real-world clinical outcomes and device performance of the OneRF Ablation System. The study focuses on…

Drug Resistant EpilepsyRefractory Epilepsy

Estimated

~$10 – $1,050

Actual pay is set by the research site.

NeuroOne Medical Technologies CorporationNCT07546253

Phase 1

A Phase 1b and 2 Study of Roginolisib (IOA-244) Combined With Obinutuzumab Followed by Venetoclax in Patients With Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL) After Progression on Prior Bruton Tyrosine Kinase (BTK) Inhibitors

This is a Phase 1b and 2, open-label, single-arm study evaluating the safety, tolerability, and efficacy of roginolisib (IOA-244) in combination with obinutuzu…

Chronic Lymphocytic Leukemia (CLL)Refractory Chronic Lymphocytic Leukemia

Estimated

~$150 – $4,500

Actual pay is set by the research site.

Dana-Farber Cancer InstituteNCT07847957

Phase 3

A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC)

This study will test a study drug called cemiplimab to see if it can help treat early-stage Cutaneous Squamous Cell Carcinoma (CSCC), a type of skin cancer. Ce…

Cutaneous Squamous Cell Carcinoma (CSCC)

Estimated

~$50 – $2,100

Actual pay is set by the research site.

Regeneron PharmaceuticalsNCT06585410

Observational

RIsEStroke (Recovery Insights Into Early Mobility Post Stroke)

This study is designed to better understand how patients with severe stroke move during their hospital stay. It will track their activity using a small wearabl…

Acute Ischemic Stroke

Estimated

~$10 – $750

Actual pay is set by the research site.

Wake Forest University Health SciencesNCT07638462

Sarcopenia Characterization Using Magnetic Resonance Fingerprinting and Phosphorous Magnetic Resonance Spectroscopic Imaging Evaluation (SUSIE)

The goal of the proposed research is to investigate Magnetic Resonance (MR) Fingerprinting and P-MRS (Phosphorus-31 MR Spectroscopy) imaging for characterizati…

Sarcopenia

Estimated

~$10 – $750

Actual pay is set by the research site.

The Cleveland ClinicNCT04869813

Blue Light Cystoscopy With Cysview® Registry

Registry study to gather more information on the current use of Blue Light Cystoscopy with Cysview (BLCC) in urologists' practices.

Bladder Cancer

Estimated

~$10 – $1,125

Actual pay is set by the research site.

PhotocureNCT02660645

Observational

Self-Directed Upper Extremity Gaming in Inpatients With Stroke: A Feasibility Study

STRIVE uses a camera mounted on the in-room TV and a connected laptop to track arm and hand movements during gameplay via markerless motion capture. No control…

Stroke

Estimated

~$10 – $1,125

Actual pay is set by the research site.

Milap SandhuNCT07806097

A Novel Molecular Approach to Blood DNA Screening for Cancer: Specificity Assessment (The NOMAD Study)

This study is being done to establish "normal' values for a new blood test and urine test approach to cancer screening. Patients undergo blood and urine sample…

Hematopoietic and Lymphoid System NeoplasmMalignant Solid Neoplasm

Estimated

~$10 – $750

Actual pay is set by the research site.

Mayo ClinicNCT06192875

Phase 1

A Phase 1b/II Study of Intratumoral CD40 Agonist 2141-V11 in Combination With Anti PD-1 and 5-Fluorouracil Therapy in Patients With Advanced Gastroesophageal Adenocarcinoma

The purpose of this study is to find out whether adding the drug 2141-V11 to standard treatment (anti-PD-1 immunotherapy with or without 5-FU) is a safe treatm…

Esophageal CancerAdvanced Esophageal CancerGastric Cancer+5 more

Estimated

~$150 – $3,000

Actual pay is set by the research site.

Memorial Sloan Kettering Cancer CenterNCT07818018

Phase 2

An Extension Study to Monitor Long-Term Safety of LUM-201 Treatment in Children With Idiopathic Growth Hormone Deficiency

This is a multi-national trial. The trial aims to study the long-term safety of LUM-201 in subjects with Idiopathic Pediatric Growth Hormone Deficiency (iPGHD)…

Growth Hormone Deficiency

Estimated

~$75 – $2,800

Actual pay is set by the research site.

Lumos PharmaNCT05796440

Phase 1

A Pilot Study of Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Bone Marrow or Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies

This research is being done to investigate the safety and effectiveness of Darzalex Faspro (daratumumab and hyaluronidase-fihj) (a monoclonal antibody that tar…

Hematologic MalignancyBone Marrow Transplant RejectionAcute Myeloid Leukemia (AML)+9 more

Estimated

~$150 – $3,000

Actual pay is set by the research site.

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins